Jaypirca receives FDA approval for first-line treatment of CLL and SLL in adults with no known 17p deletion

Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who need to begin treatment now have another first-line option. On October 2, 2026, the U.S. Food and Drug Administration (FDA) approved Lilly’s pirtobrutinib (brand name Jaypirca) for previously untreated adults with no known deletion of the short arm of chromosome 17 (17p deletion), moving the drug beyond the treatment of relapsed or refractory disease into an earlier treatment setting.

Pirtobrutinib is a noncovalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor that binds to the BTK protein to inhibit its activity. This expanded indication allows eligible patients to receive the drug as their initial treatment. However, the approval includes a specific chromosomal criterion, and the results cannot be directly generalized to patients with a 17p deletion.

The approval is supported by the phase 3 BRUIN CLL-313 trial. Both the FDA announcement and OncLive’s report stated that the study enrolled 282 previously untreated patients with CLL or SLL without a 17p deletion and randomly assigned them to two groups: one received pirtobrutinib continuously until disease progression, while the other received six cycles of bendamustine plus rituximab. The trial used an open-label design, with the primary efficacy endpoint assessed by an independent review committee.

At an estimated median follow-up of 28 months for progression-free survival, median progression-free survival could not yet be estimated in the pirtobrutinib group and was 33.5 months in the control group; the hazard ratio for disease progression or death was 0.20. This indicates a marked reduction in relative risk during follow-up. It does not mean that the disease was cured, nor can it be used to calculate how much longer each patient’s disease would remain controlled.

The difference in disease control has not yet translated into a definitive conclusion about overall survival. Both OncLive and the FDA stated that overall survival data remained immature at the primary analysis, with neither group reaching median overall survival; there were 3 deaths in the pirtobrutinib group and 10 in the control group. In addition, this trial used chemoimmunotherapy as the comparator, so its results alone cannot establish that pirtobrutinib is superior to other first-line targeted regimens.

Beyond efficacy, the safety of continuous treatment is also a key consideration. The FDA stated that 28% of patients in the pirtobrutinib group experienced serious adverse reactions, with common adverse reactions including upper respiratory tract infection, rash, and COVID-19. The prescribing information also lists warnings for infections, hemorrhage, cytopenias, cardiac arrhythmias, and hepatotoxicity. This approval expands initial treatment options, while further data are still needed to clarify the long-term survival benefit and the burden of continuous treatment.